In the last trading session, 1.8 million uniQure N.V (NASDAQ:QURE) shares changed hands as the company’s beta touched 0.26. With the company’s per share price at $8.76 changed hands at -$0.2 or -2.23% during last session, the market valuation stood at $473.71M. QURE’s last price was a discount, traded about -118.95% off its 52-week high of $19.18. The share price had its 52-week low at $3.73, which suggests the last value was 57.42% up since then. When we look at uniQure N.V’s average trading volume, we note the 10-day average is 1.79 million shares, with the 3-month average coming to 1.16 million.
Analysts gave the uniQure N.V (QURE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended QURE as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. uniQure N.V’s EPS for the current quarter is expected to be -0.96.
uniQure N.V (NASDAQ:QURE) trade information
Instantly QURE was in red as seen at the end of in last trading. With action -17.36%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -50.40%, with the 5-day performance at -17.36% in the red. However, in the 30-day time frame, uniQure N.V (NASDAQ:QURE) is -28.37% down. Looking at the short shares, we see there were 3.05 million shares sold at short interest cover period of 3.22 days.
The consensus price target for the stock as assigned by Wall Street analysts is 27, meaning bulls need an upside of 67.56% from its current market value. According to analyst projections, QURE’s forecast low is 24 with 30 as the target high. To hit the forecast high, the stock’s price needs a -242.47% plunge from its current level, while the stock would need to soar -173.97% for it to hit the projected low.
uniQure N.V (QURE) estimates and forecasts
Year-over-year growth is forecast to reach 45.20% up from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 6.1M. 10 analysts are of the opinion that uniQure N.V’s revenue for the current quarter will be 6.87M. The company’s revenue for the corresponding quarters a year ago was 7.87M and 10.32M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -22.54%. The estimates for the next quarter sales put growth at -33.36%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -9.66%. The 2025 estimates are for uniQure N.V earnings to increase by 21.08%, but the outlook for the next 5-year period is at 31.22% per year.
QURE Dividends
uniQure N.V is expected to release its next quarterly earnings report on 2025-Feb-26.
uniQure N.V (NASDAQ:QURE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.59% of uniQure N.V shares while 77.61% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 84.90%. There are 77.61% institutions holding the uniQure N.V stock share, with VESTAL POINT CAPITAL, LP the top institutional holder. As of 2024-06-30, the company held 9.7692% of the shares, roughly 4.75 million QURE shares worth $21.28 million.
NANTAHALA CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 5.4511% or 2.65 million shares worth $11.87 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were abrdn Healthcare Investors and Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND . With 812.69 shares estimated at $7.12 million under it, the former controlled 1.50% of total outstanding shares. On the other hand, Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND held about 1.36% of the shares, roughly 733.5 shares worth around $6.43 million.
